PubRank

William E Evans

Author PubWeight™ 226.88‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007 17.68
2 Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002 11.83
3 Treatment of acute lymphoblastic leukemia. N Engl J Med 2006 11.30
4 The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012 9.89
5 Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009 7.95
6 Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014 5.37
7 A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009 5.22
8 Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet 2011 4.93
9 Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012 4.41
10 Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004 4.21
11 Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004 4.16
12 Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet 2009 3.71
13 Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 2003 3.57
14 Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006 2.95
15 Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 2012 2.82
16 Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 2003 2.77
17 Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009 2.72
18 Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol 2010 2.52
19 Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 2011 2.52
20 The Pediatric Cancer Genome Project. Nat Genet 2012 2.49
21 The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther 2013 2.39
22 Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet 2013 2.38
23 Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 2007 2.38
24 Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 2010 2.37
25 Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 2013 2.34
26 Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009 2.20
27 Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet 2005 1.94
28 Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer 2005 1.93
29 Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood 2012 1.90
30 Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood 2008 1.89
31 Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood 2011 1.88
32 Molecular haplotyping of genomic DNA for multiple single-nucleotide polymorphisms located kilobases apart using long-range polymerase chain reaction and intramolecular ligation. Pharmacogenetics 2002 1.82
33 Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst 2013 1.81
34 Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc 2013 1.80
35 Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 2003 1.79
36 Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 2008 1.79
37 Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006 1.71
38 Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 2008 1.67
39 PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet 2012 1.66
40 Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol 2011 1.60
41 Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol 2014 1.58
42 Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 2005 1.58
43 Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005 1.53
44 Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 2006 1.52
45 Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007 1.52
46 Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003 1.51
47 PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet 2014 1.49
48 Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 2005 1.46
49 Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet 2013 1.45
50 Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 2005 1.42
51 Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 2003 1.40
52 ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2012 1.39
53 In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med 2008 1.37
54 Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat Med 2011 1.34
55 A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol 2013 1.32
56 Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol 2014 1.31
57 A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer Res 2003 1.27
58 Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007. J Clin Oncol 2012 1.25
59 The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood 2005 1.25
60 Statement by members of the Ponte di Legno Group on the right of children to have full access to essential treatment for acute lymphoblastic leukemia. Pediatr Blood Cancer 2004 1.18
61 Structure and dynamics of thioguanine-modified duplex DNA. J Biol Chem 2002 1.18
62 Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 2012 1.17
63 Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol 2010 1.16
64 A novel CRM1-mediated nuclear export signal governs nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase following genotoxic stress. J Biol Chem 2003 1.13
65 Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood 2005 1.11
66 Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol 2014 1.10
67 Pharm.D.-only investigators are critical to the profession: let's preserve the fellowship as an equally important way to prepare future clinical pharmaceutical scientists: or the case against the "all-Ph.D.". Pharmacotherapy 2009 1.08
68 De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood 2002 1.08
69 Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert Opin Drug Saf 2010 1.08
70 Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells. PLoS Comput Biol 2010 1.07
71 The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia. J Natl Cancer Inst 2008 1.04
72 Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics 2013 1.03
73 A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2002 1.02
74 Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression. Hum Mol Genet 2007 1.01
75 HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy. Clin Chem 2002 1.01
76 Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis. Blood 2004 0.98
77 A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics 2004 0.96
78 Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocols. Blood 2006 0.96
79 Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res 2007 0.95
80 Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 2002 0.94
81 Lymphoid gene expression as a predictor of risk of secondary brain tumors. Genes Chromosomes Cancer 2005 0.94
82 Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood 2005 0.93
83 Pharmacogenomics in pediatric leukemia. Curr Opin Pediatr 2010 0.93
84 Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing. Int J Data Min Bioinform 2011 0.91
85 Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model. J Biol Chem 2014 0.91
86 Thiopurine pathway. Pharmacogenet Genomics 2010 0.90
87 The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance. Haematologica 2013 0.90
88 Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity. Trends Mol Med 2002 0.89
89 Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics 2014 0.89
90 Pharmacogenetics in acute lymphoblastic leukemia. Semin Hematol 2009 0.88
91 Msh2 deficiency attenuates but does not abolish thiopurine hematopoietic toxicity in msh2-/- mice. Mol Pharmacol 2003 0.88
92 Childhood acute lymphoblastic leukemia. Rev Clin Exp Hematol 2002 0.86
93 Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. Clin Cancer Res 2002 0.86
94 Pharmacogenomics of acute leukemia. Annu Rev Pharmacol Toxicol 2006 0.86
95 Epigenetic regulation of human gamma-glutamyl hydrolase activity in acute lymphoblastic leukemia cells. Am J Hum Genet 2006 0.85
96 Pharmacogenomics in cancer therapy: is host genome variability important? Trends Pharmacol Sci 2004 0.85
97 New developments in the epidemiology of cancer prognosis: traditional and molecular predictors of treatment response and survival. Cancer Epidemiol Biomarkers Prev 2006 0.84
98 Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002 0.84
99 Global gene expression as a function of germline genetic variation. Hum Mol Genet 2005 0.83
100 Cancer pharmacogenomics may require both qualitative and quantitative approaches. Cell Cycle 2005 0.83
101 Pharmacogenomics of acute lymphoblastic leukemia. Curr Opin Hematol 2006 0.82
102 Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cancer Chemother Pharmacol 2013 0.82
103 Closing the gap between science and clinical practice: the thiopurine S-methyltransferase polymorphism moves forward. Pharmacogenetics 2004 0.82
104 TELAML1-positive ALL: a discordant genotype. Cell Cycle 2005 0.81
105 Rapid genotyping of common deficient thiopurine S-methyltransferase alleles using the DNA-microchip technique. Eur J Hum Genet 2006 0.81
106 Concordant gene expression in leukemia cells and normal leukocytes is associated with germline cis-SNPs. PLoS One 2008 0.80
107 Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia. Clin Pharmacol Ther 2003 0.79
108 The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7-9, 2011. Pediatr Blood Cancer 2012 0.79
109 Are children with lesser-risk B-lineage acute lymphoblastic leukemia curable with antimetabolite therapy? Nat Clin Pract Oncol 2008 0.78
110 TPMT genetic variations in populations of the Russian Federation. Pediatr Blood Cancer 2009 0.78
111 Vincristine pharmacogenomics: 'winner's curse' or a different phenotype? Pharmacogenet Genomics 2016 0.78
112 Gene expression as a drug discovery tool. Nat Genet 2004 0.77
113 High-dose methotrexate: the rationale... J Pediatr Hematol Oncol 2009 0.77
114 Asymptomatic renal cell carcinoma as a finding of Bardet Biedl syndrome. Ophthalmic Genet 2008 0.76
115 Mathematical modeling of folate metabolism. Wiley Interdiscip Rev Syst Biol Med 2013 0.76
116 Differences in smooth pursuit eye movement between posttraumatic stress disorder with secondary psychotic symptoms and schizophrenia. Schizophr Res 2003 0.76
117 Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model. Pharmacogenet Genomics 2014 0.76
118 Therapeutic horizons--the human genome. J Am Pharm Assoc (Wash) 2002 0.76
119 Is mega dose of methotrexate beneficial to patients with acute lymphoblastic leukemia? Leuk Lymphoma 2006 0.76
120 Continue to study childhood ALL. Blood 2008 0.75
121 Genetics of pleiotropic effects of dexamethasone. Pharmacogenet Genomics 2017 0.75